LVR-Klinikum Düsseldorf Hospital of the Heinrich-Heine University ...

LVR-KLINIKUM DÜsseLDORF – hOsPITaL OF The heINRIch-heINe UNIVeRsITY DÜsseLDORF
were used that had been tested in other contexts (stress
relief procedures, competency training, problem-solving
training). The results show that behaviour therapy of atrisk
persons in the early prodromal stage can successfully
prevent the transition to late-prodromal or psychotic stages
in many cases.
Early intervention in late-prodromal psychosis
M. Streit, M. List, S. Ruhrmann, J. Klosterkötter, W. Gaebel
Project period: 1999–2003
Financing: Federal Ministry or Education and Training
(Funding 01 GI 9935 to S. Ruhrmann, Cologne)
This multi-centre clinical trial within the Competence
Network on Schizophrenia assessed the efficacy of
amisulpride in persons in late pre-psychotic prodromal
stages of schizophrenia. The study was performed in
a randomised, open, parallel-group design in in- and
outpatients in early adulthood. Study participants were
treated either with amisulpride plus clinical management
or only with clinical management. Amisulpride was used
in the dose range 50-800 mg. Primary outcomes were the
improvement of prodromal symptoms and the prophylactic
efficacy measured as the ratio of the probability in the two
groups of developing manifest psychosis during the study.
This atypical antipsychotic drug was effective in reducing
both pre-existing symptoms and the transition rate to
psychosis. Longer follow-up is necessary to determine
whether these transitions are truly reduced or just delayed.
Secondary prevention of schizophrenia: a randomised
controlled study (PREVENT)
B. Janssen (from 2009), G. Winterer (until 2009), E. Streit,
K. Teufel, A. Bechdolf, J. Klosterkötter, W. Gaebel
Project period: since 2008
Financing: German Research Association (Funding to J.
Klosterkötter, Cologne)
The “PREVENT” multi-centre study, initiated by the
Cologne Early Diagnosis and Treatment Centre, builds
immediately on the results of both of the above studies by
the Competence Network on Schizophrenia. In the threearmed
study design, a cognitive behaviour therapy treatment
is being tested directly against low-dose antipsychotic
treatment or placebo for the first time in people at increased
risk of psychosis. The study period is a total of three and a
half years.
112
3.1.4.3 Borderline personality disorder
Director: J. Malevani
Scientific assistants: D. Gescher, A. Ruttman,
H. Lüthcke
The research group’s work focuses on both epidemiological
healthcare aspects and clinical pharmaceutical aspects
of borderline personality disorder. In the first phase,
healthcare patterns for these patients were investigated
and evaluated using a retrospective naturalistic study
design employing DGPPN-BADO data from 2004-2008.
Assessments included the following parameters: admission
modality (referral, legal background, prior treatment),
demographic aspects (age, sex distribution, education,
training, professional situation) and aftercare. As a first
interim result it was found that the treatment of people with
borderline disorder on a specialised ward – be it secure
or open – has a beneficial effect on outpatient treatment
continuation. In a naturalistic retrospective approach,
sociodemographic features of inpatients with borderline
disorder are assessed using DGPPN-BADO datasets.
Because of the early onset of borderline symptoms in youth
or early adulthood, basic deficits in shaping one’s life can
occur, which lead to the early termination of education and
training, problems in work life and social disintegration. The
analysis of sociodemographic features could therefore yield
essential epidemiological information that is relevant for the
estimation of psychosocial risk factors and that may have
prognostic value and be relevant for therapy.